imatinib mesylate has been researched along with Jejunal Diseases in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Altavilla, G; Arrigo, C; Pitini, V | 1 |
1 other study(ies) available for imatinib mesylate and Jejunal Diseases
Article | Year |
---|---|
Dasatinib induces a response in chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blood Cell Count; Dasatinib; Female; Fusion Proteins, bcr-abl; Hemorrhage; Humans; Imatinib Mesylate; Jejunal Diseases; Leukemia, Lymphocytic, Chronic, B-Cell; Liver Neoplasms; Magnetic Resonance Imaging; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Rituximab; src-Family Kinases; Thiazoles; Tomography, X-Ray Computed; Vidarabine | 2009 |